.Nature Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of people with HER2+ enhanced bosom cancer and also active or even steady brain metastases presented consistent intracranial activity as well as systemic efficiency of T-DXd.